Halloween Sale Ends On October 31st

BPC-157 10mg

Shop

BPC-157 10mg · Research brief

Peptide Purity 98 vs 99: What the Extra 1% Means

54 WORDS

Short answer

The gap between a 98% and a 99% peptide isn't one percentage point. It's double the impurity load: 2% non-target material versus 1%, which in a 10 mg vial is roughly 0.2 mg versus 0.1 mg of something that isn't the sequence you ordered. We supply research-grade peptides and read a lot of chromatograms.

Key takeaways

  • A 98% peptide carries up to twice the non-target material of a 99% peptide, which in a 10 mg vial is roughly 0.2 mg versus 0.1 mg.
  • HPLC purity is a peak-area ratio measured by UV absorbance, commonly at 214 nm, so salts, trifluoroacetate counterion and residual water are invisible to it.
  • Net peptide content and HPLC purity are two different measurements, and the gross weight of a vial is never all peptide.
  • The most common impurities in synthetic peptides are sequence relatives: single-residue deletions, truncations, epimers, methionine sulfoxide and deamidated variants.
  • A steeper HPLC gradient can inflate an apparent purity figure by burying co-eluting impurities under the main peak.
  • Frameworks such as ICH Q3A treat impurities at the 0.1% level as worth identifying, which is a useful benchmark for reading any impurity table.
  • Every lot we release at Real Peptides ships with a batch-specific certificate of analysis, because lot-to-lot consistency protects a study more reliably than a single high percentage.

The gap between a 98% and a 99% peptide isn't one percentage point. It's double the impurity load: 2% non-target material versus 1%, which in a 10 mg vial is roughly 0.2 mg versus 0.1 mg of something that isn't the sequence you ordered.

We supply research-grade peptides and read a lot of chromatograms. Most buyers comparing peptide purity 98 vs 99 are asking a narrower question than they should be. The number matters less than what the leftover fraction is made of, and which analytical method produced the figure in the first place.

What's the difference between peptide purity 98 vs 99?

A 98% peptide contains up to 2% non-target material by HPLC peak area; a 99% peptide contains up to 1%, halving the impurity mass per vial. Whether that gap changes your data depends on the assay. Reference standards and receptor binding work are sensitive to it. Many cell-based screens aren't.

The common oversimplification is that purity tells you how much peptide is in the vial. It doesn't. HPLC purity is a ratio of UV-absorbing peak areas, so salts, counterions and residual water never appear in it. This piece covers what that final percentage point is usually made of, why the same vial can read as 98% or 99% depending on the method, and when the higher grade genuinely earns its price.

What that final percentage point is usually made of

The 1% to 2% that isn't your target sequence is almost never inert filler. Most research peptides are built by Fmoc solid-phase peptide synthesis, where amino acids are coupled one residue at a time and every coupling step carries a small failure rate. The impurities that survive preparative purification are chemical relatives of the peptide itself: deletion sequences missing a single residue, truncated chains that stalled mid-synthesis, incompletely deprotected chains still carrying a protecting-group fragment, and epimers where one residue flipped to the D-configuration during activation.

Then there's post-synthesis damage. Methionine oxidizes to methionine sulfoxide. Asparagine deamidates to aspartate, shifting the molecular weight by a single unit. Cysteine-containing sequences can form intermolecular disulfide dimers if the lyophilized powder picks up moisture.

Here's why that matters for anyone weighing peptide purity 98 vs 99: a des-amino-acid analog can be structurally close enough to occupy the same receptor and behave as a weak agonist or an antagonist. One percent of a near-isosteric analog is not the same experimental risk as one percent of residual water. In our experience reading certificates across a lot of batches, the most useful line on a certificate of analysis isn't the headline purity figure. It's the named impurity table sitting underneath it.

The purity number describes a method, not the molecule

Purity by HPLC is a ratio, not a census. Reverse-phase HPLC separates species by hydrophobicity on a C18 column, the detector measures UV absorbance (commonly at 214 nm, where the peptide bond itself absorbs), and purity is the target peak area divided by the total integrated area. Change the method and the number moves with it.

This is the part most sourcing guides skip: the most common way a 99% peptide becomes a 98% peptide isn't degradation, it's a shallower gradient. A steep, fast gradient compresses closely related impurities under the main peak, and anything that co-elutes gets counted as product. Run the same vial on a longer gradient, or a different column chemistry, and previously buried shoulders resolve into their own peaks. The peptide didn't change. The resolution did.

Two further limits are worth knowing. Detection at 214 nm is effectively blind to non-UV-absorbing material, so inorganic salts, trifluoroacetate counterion and residual water from lyophilization don't register in the HPLC figure at all, which is why net peptide content is a separate measurement entirely. And mass spectrometry, usually ESI-MS or MALDI-TOF, confirms identity by molecular weight but isn't a quantitative purity method on its own. A certificate carrying both results, with the method conditions printed, tells you far more than a bare percentage ever will.

When the extra point earns its price, and when it doesn't

The decision is application-driven, not aspirational. If the peptide serves as an analytical reference standard, anchors quantitative LC-MS calibration, or feeds receptor binding, enzyme kinetics or structural work where one bioactive analog would confound the readout, the higher grade with a documented impurity profile is the defensible choice. For cell-based screening, stability and handling studies, method development or preliminary range-finding, 98% material with a clean, identified impurity list is usually adequate, and spending the difference on additional replicates often buys more statistical power than the extra percentage point does.

So what does our team watch more closely than the headline grade? Lot-to-lot consistency. A supplier reporting 98.4%, 98.6% and 98.5% across three consecutive batches is easier to build a multi-month study on than one that reports a single 99.1% result and won't show you the lots before it. That's why batch-specific documentation matters more in the peptide purity 98 vs 99 conversation than the number on the label. Research-use-only compounds aren't approved drugs and aren't for human or veterinary consumption, and any question touching an animal model belongs with your institution's veterinarian and animal care committee rather than a supplier.

Peptide Purity 98 vs 99: Side-by-Side Comparison

The table below translates the percentage gap into the terms that actually affect bench work: impurity mass, likely impurity classes, and documentation quality. Read the Bottom Line column first if you're mid-sourcing decision.

Consideration 98% HPLC purity 99% HPLC purity Bottom Line
Non-target material per 10 mg vial Up to roughly 0.2 mg is something other than the target sequence Up to roughly 0.1 mg of non-target material Halving impurity mass matters when the impurity is structurally active, far less when it's water or salt
Likely impurity classes Deletion and truncated sequences, oxidation and deamidation products, residual protecting groups Same chemical classes at lower total load, though individual peaks near the 0.1% integration threshold may go unreported Impurity identity outranks impurity total; ask for the named impurity table at either grade
Best-fit applications Cell-based screening, method development, handling and stability work Reference standards, quantitative LC-MS, receptor binding, structural characterization Match the grade to assay sensitivity instead of defaulting to the highest available number
Analytical documentation Frequently reported as a percentage with no method conditions attached More often paired with a fuller certificate including mass confirmation A certificate printing column, gradient and wavelength beats a higher unexplained percentage every time
Cost and lot availability Lower cost, wider availability, more historical batches to compare Premium pricing, occasionally smaller or less frequent batches Consistency across several lots protects a long study better than one exceptional certificate does

What If: Purity Spec Scenarios

These are the four questions we field most often once a researcher starts taking peptide purity 98 vs 99 seriously.

What if my certificate says 99% but the impurity table is blank?

Request the chromatogram and the method conditions before you order. A purity figure without a trace, a column, a gradient and a detection wavelength is an unverifiable claim, and a blank impurity table usually means impurities weren't identified rather than weren't present. Peaks sitting near the 0.1% integration threshold are exactly the ones a short gradient hides.

What if two suppliers report different purity for the same sequence?

Compare methods before you compare numbers. Different column chemistries, gradient slopes and detection wavelengths routinely produce different purity values from the same material, and neither lab is necessarily wrong. The supplier whose method resolves more peaks will often report the lower number, which is a sign of a more honest assay rather than a worse peptide.

What if my assay results shifted between lots of the same peptide?

Check net peptide content and counterion load before you suspect the purity grade. Two lots at the same HPLC purity can differ in residual water and trifluoroacetate, which changes how much active peptide you actually weighed out. Oxidation state is the other usual suspect, particularly for methionine-containing sequences stored without rigorous temperature and moisture control.

What if I'm only doing method development or a preliminary screen?

98% material with an identified impurity profile is generally the rational spend. Method development mostly needs a stable, well-characterized input rather than a maximal one, and the money saved often funds the replicates that determine whether your effect is real. Save the premium grade for the confirmatory experiments where a single bioactive analog could change the conclusion.

The Uncomfortable Truth About Purity Percentages

Let's be direct about this: for most laboratory work, moving from 98% to 99% changes less than buyers expect, and moving from an undocumented impurity profile to a named one changes considerably more. A 99% figure with no chromatogram, no method conditions and no mass confirmation is a marketing number. A 98.3% figure with a resolved trace, an identified impurity list and three comparable prior lots is data you can build on. Purity grades have become a shorthand for quality because they're easy to print on a label, and that convenience is precisely what makes them easy to overstate.

If you want to see how we document that, every batch-specific certificate is published on our certificates of analysis page, the full research catalog including BPC-157, TB-500 and GHK-Cu sits in the shop, and ordering and fulfilment details are on our ordering information page.

Peptide purity 98 vs 99 is one of those specifications that looks like a simple ranking and behaves like a research question. The percentage tells you how much of your vial isn't the sequence; only the chromatogram tells you whether that fraction is inert salt or a single-residue analog capable of binding the target you're studying. Ask for the trace, ask which gradient produced it, and ask to see the two lots before yours. Researchers who make that a habit stop paying a premium for decimal points and start paying for information, which is the only part of a purity spec that ever protected an experiment.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add vials.

Start a pack

Questions

Both figures normally come from reverse-phase HPLC, where the peptide is separated on a C18 column and UV absorbance is measured, most often at 214 nm because the peptide bond absorbs there. Purity is calculated as the target peak's area divided by the total integrated peak area, expressed as a percentage. Identity is confirmed separately by mass spectrometry, typically ESI-MS or MALDI-TOF, which verifies molecular weight but does not by itself quantify purity.
It depends entirely on how sensitive your readout is to a structurally similar analog. For analytical reference standards, quantitative LC-MS calibration and receptor binding or enzyme kinetics work, the higher grade with a documented impurity table is usually the defensible spend. For cell-based screening, handling studies or method development, 98% material with an identified impurity list is commonly adequate, and the saved budget often buys more useful replicates.
No, and this is the single most common misreading of a certificate. HPLC purity is a ratio among UV-absorbing species, so it excludes inorganic salts, trifluoroacetate counterion left over from preparative purification, and residual water from lyophilization. Net peptide content is a separate measurement, and gross vial mass is routinely higher than the mass of actual peptide it contains.
Most are chemical relatives of the target sequence produced during Fmoc solid-phase synthesis: deletion sequences missing a single residue, truncated chains, incompletely deprotected chains carrying a protecting-group fragment, and epimers with one residue in the D-configuration. Post-synthesis changes add methionine sulfoxide from oxidation and aspartate from asparagine deamidation. Cysteine-containing sequences can also form disulfide-linked dimers if moisture reaches the powder.
Yes, routinely, and neither result is necessarily incorrect. Column chemistry, gradient slope, run length and detection wavelength all affect how well closely related impurities resolve from the main peak. A steeper gradient compresses those impurities under the target peak so they get counted as product, which is why the lab reporting the lower number is often running the more discriminating method.
HPLC purity answers what fraction of the UV-absorbing material is your target sequence; net peptide content answers what fraction of the vial mass is peptide at all. A lot can be 99% pure by HPLC while a meaningful share of the powder weight is counterion and water. If your work requires accurate mass-based preparation of solutions, net peptide content is the more relevant figure of the two.
Look for the HPLC chromatogram itself, the method conditions (column, gradient, flow rate and detection wavelength), a mass spectrometry result confirming molecular weight, an identified impurity table, and the specific lot number the document refers to. Frameworks such as ICH Q3A treat impurities around the 0.1% level as worth identifying for drug substances, which is a reasonable benchmark when judging how thorough an impurity table is.
Yes. Purity is measured at release, not permanently guaranteed, and oxidation, deamidation and dimer formation all progress over time depending on temperature, moisture exposure and the sequence itself. Lyophilized powder is considerably more stable than material in solution, and repeated freeze-thaw cycles and humid air are the two conditions most often implicated when a lot performs differently months after receipt.
Work where a single closely related analog could alter the result. That includes analytical reference standards, quantitative mass spectrometry calibration, receptor binding and competitive displacement assays, enzyme kinetics, and structural studies such as crystallography or NMR where heterogeneity degrades the data directly. Screening, formulation handling trials and method development are usually tolerant of 98% material with a known impurity profile.
Because multi-month studies compare data across vials, and drift between lots introduces variability that looks exactly like a biological effect. A supplier reporting tightly clustered results across several consecutive batches, with a certificate for each, gives you a stable input to reason from. A single outstanding percentage with no batch history behind it tells you almost nothing about the vial arriving next quarter.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now